Effects of Inclisiran on Systemic Inflammatory Biomarkers: A Systematic Review

Warham[1*] , Nurul Fitriani Andi Padri[2] , Wiking Zeth[3] , Annisa Istiqamah Ahmad[4] , Asdwiyenti Miftahulresty Aksi[5], Azhim Asshiddiq Suhardi Andi Ara[6]

[1]Sendana I Community Health Center, Majene Regency, Indonesia
[2]Noling Community Health Center, Luwu Regency, Indonesia
[3]East Walenrang Community Health Center, Luwu Regency, Indonesia
[4] Bambang Community Health Center, Mamasa Regency, Indonesia
[5]Bahteramas Regional General Hospital, Kendari Regency, Indonesia
[6]Padang Lambe Community Health Center, Palopo Regency, Indonesia
*Corresponding Author:
Email: warhampeters20@gmail.com

Abstract.

Background: Inclisiran is a novel small interfering RNA (siRNA) therapy that specifically targets proprotein convertase subtilisin/kexin type 9 (PCSK9), thereby introducing an innovative method for the regulation of lipid levels. The implications of this intervention regarding systemic inflammatory biomarkers necessitate comprehensive investigation. Objective: To thoroughly evaluate how inclisiran influences inflammatory markers, especially high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α), among a group of people identified with hypercholesterolemia or atherosclerotic cardiovascular disease. Methods: A thorough systematic literature review was performed in accordance with the PRISMA 2020 guidelines. A meticulous search was undertaken across three databases (Scopus, ScienceDirect, PubMed) encompassing the timeframe from January 2017 to December 2025. Two independent reviewers engaged in the processes of filtering, extracting information, and quality evaluation by using the Cochrane RoB 2.0 tool, specifically crafted for randomized controlled trials (RCTs). Results: Out of an initial cohort of 304 records, 11 studies met the predetermined inclusion criteria, encompassing 4 noteworthy phase 2-3 randomized controlled trials (RCTs) (ORION-1, -9, -10, -11). Inclisiran revealed considerable reductions in LDL-C concentrations (varying from 47.9% to 52.6%), while demonstrating neutral effects on hs-CRP levels, which encompassed non-significant increases when compared to placebo (for example, from 3.5% to 8.5%). No investigations have provided data pertaining to IL-6 or TNF-α. All RCTs evaluated demonstrated a significantly low propensity for bias. Conclusions: Current empirical research indicates that inclisiran does not significantly influence systemic hs-CRP levels and lacks comprehensive data regarding other essential inflammatory biomarkers. The enhancements noted in cardiovascular wellness tied to this medication seem to be chiefly dictated by major declines in LDL-C concentrations, instead of variations in overall inflammation. Upcoming research on heart health results must incorporate a wide selection of inflammatory indicators to fully explain the complicated impacts of inclisiran.

Keywords: *HS-CRP; Inclisiran; IL-6; TNF-α and LDL-cholesterol.*

I. INTRODUCTION

Atherosclerotic cardiovascular disease (ASCVD) continues to be the predominant etiological factor of mortality on a global scale, contributing to an estimated 18 million fatalities each year.[1] Beyond its conventional characterization as a disorder primarily associated with lipid storage, atherosclerotic cardiovascular disease (ASCVD) is presently acknowledged as a chronic inflammatory condition distinguished by intricate interactions among lipid accumulation, endothelial dysfunction, and the activation of the immune system.[1,2] This transformative paradigm engenders significant ramifications for therapeutic approaches, indicating that the most effective reduction of cardiovascular risk may necessitate the concurrent targeting of both lipid metabolism and inflammatory mechanisms.Elevated concentrations of low-density lipoprotein cholesterol (LDL-C) represent a thoroughly validated causal risk determinant for atherosclerotic cardiovascular disease (ASCVD), bolstered by comprehensive genetic, epidemiological, and interventional data that substantiate the efficacy of aggressive LDL-C reduction in mitigating cardiovascular events.[3,4] Nevertheless, a considerable residual risk for cardiovascular events continues to exist even in individuals who attain the LDL-C levels recommended by clinical guidelines while undergoing statin treatment, with inflammatory mechanisms playing a crucial role in the persistence of this residual risk.[5,6] The seminal CANTOS trial elucidated that the modulation of inflammation via canakinumab, an interleukin-1β (IL-1β)

inhibitor, culminated in a reduction of cardiovascular events that was independent of the attenuation of LDL-C levels, thereby affirming inflammation as a viable therapeutic target in atherosclerotic cardiovascular disease (ASCVD).

Proprotein convertase subtilisin/kexin type 9 (PCSK9) has arisen as an essential moderator of LDL receptor equilibrium and a substantiated pharmacological objective for lipid reduction.[8] Inclisiran (ALN-PCSsc) epitomizes an innovative methodology for PCSK9 suppression via RNA interference (RNAi) technology. This artificially formulated small interfering RNA (siRNA) conjugated to N-acetylgalactosamine specifically engages hepatocyte PCSK9 messenger RNA, culminating in prolonged PCSK9 protein attenuation and augmented LDL receptor expression.[9,10] In contrast to monoclonal antibody PCSK9 antagonists necessitating regular subcutaneous administrations, inclisiran's distinctive pharmacokinetic characteristics facilitate biannual dosing subsequent to initial delivery, potentially enhancing compliance and practical efficacy.[11]The ORION clinical trial initiative thoroughly assessed inclisiran's effectiveness and safety across heterogeneous patient demographics, encompassing individuals with atherosclerotic cardiovascular disease, familial hypercholesterolemia, and statin intolerance.[10,12,13] These investigations consistently evidenced substantial and enduring LDL-C decrements of approximately 50% with advantageous safety characteristics. Based on this substantiation, inclisiran attained regulatory endorsement from the European Medicines Agency in 2020 and the United States Food and Drug Administration in 2021 for adults with heterozygous familial hypercholesterolemia or clinical ASCVD necessitating supplementary LDL-C reduction.[14]Beyond the reduction of lipids, nascent evidence indicates that PCSK9 may possess pleiotropic influences on inflammatory pathways. Preclinical analyses have demonstrated the presence of PCSK9 in several cell types beyond hepatocytes, such as macrophages, endothelial cells, and vascular smooth muscle cells, which could be relevant to the management of inflammatory responses.[15,16]

Furthermore, observational studies have reported associations between circulating PCSK9 levels and inflammatory biomarkers, including high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α).[17,18] The extent to which PCSK9 inhibition via inclisiran affects systemic inflammation without concurrently lowering LDL-C levels remains ambiguous, and this uncertainty bears significant consequences for elucidating its cardiovascular advantages..Considered a crucial inflammatory marker, high-sensitivity C-reactive protein (hs-CRP) offers important forecasting information concerning cardiovascular occurrences, much like acknowledged lipid indicators including low-density lipoprotein (LDL) cholesterol. Empirical investigations have substantiated that hs-CRP serves as a robust predictor of major adverse cardiovascular events (MACE), particularly within secondary preventive frameworks, where it exhibits a linear correlation with cardiovascular outcomes including myocardial infarction and cerebrovascular accident.[19] The recognition of elevated-sensitivity C-reactive protein (hs-CRP) as a vital indicator for cardiovascular risk assessment is on the rise, specifically in individuals presenting with higher levels (>2 mg/L), tied to a heightened risk of cardiovascular events.[20] IL-6, a sophisticated cytokine vital for the acute phase response and chronic inflammation, together with TNF-α, a central mediator of systemic inflammation and endothelial dysfunction, constitutes further clinically relevant inflammatory biomarkers in ASCVD.

Understanding the established function of inclisiran in reducing LDL-C levels necessitates a thorough examination of its association with inflammatory biomarkers. Comprehending inclisiran's inflammatory profile is imperative for several rationales: (1) clarifying mechanisms beyond lipid reduction that may contribute to cardiovascular advantages; (2) discerning patient demographics most predisposed to derive benefit from inclisiran therapy; (3) informing combinatorial therapeutic strategies targeting both lipid and inflammatory pathways; and (4) directing biomarker selection for ongoing cardiovascular outcome investigations.As a consequence, we executed this comprehensive review to meticulously assess the impact of inclisiran on inflammatory biomarkers, with a specific emphasis on hs-CRP, IL-6, and TNF-α, within adult cohorts experiencing hypercholesterolemia or atherosclerotic cardiovascular disease (ASCVD). Given the nascent yet contradictory evidence regarding the inflammatory ramifications of alternative PCSK9 inhibitors and the distinctive RNA interference mechanism of inclisiran, a systematic aggregation of its influence on inflammatory biomarkers is urgently warranted. This examination represents the inaugural

extensive investigation into this deficiency, yielding significant insights into its operational mechanisms and guiding the advancement of subsequent trials. Our supplementary objectives encompassed evaluating the association between decrements in LDL-C and modifications in inflammatory biomarkers, appraising the quality of existing evidence, and identifying domains of knowledge that require further inquiry.

II. METHODS

Protocol Registration and Reporting

This comprehensive examination was executed and documented in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 declaration.[23] The protocol was registered with PROSPERO (ID: CRD420251249116).

Eligibility Criteria

The parameters for qualification were articulated employing the PICO (Population, Intervention, Comparator, Outcome) framework:

Population: Persons who are 18 years of age or older and exhibit hypercholesterolemia (characterized as LDL-C concentrations equal to or surpassing 70 mg/dL), a diagnosis of atherosclerotic cardiovascular pathology, familial hypercholesterolemia, or categorized as having elevated to exceedingly high cardiovascular risk.

Intervention: Inclisiran delivered through subcutaneous injection at any dosage and duration ≥12 weeks.

Comparator: Placebo, conventional therapy (statin ± ezetimibe), active comparators (PCSK9 monoclonal antibodies, alternative lipid-modulating agents), or no intervention control.

Outcomes: It is crucial that investigations incorporate a minimum of one inflammatory biomarker, which may include high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α).

Study Design: The evaluation included randomized controlled trials (RCTs), prospective cohort investigations, case-control analyses, and observational inquiries that integrate comparative cohorts as legitimate. We excluded narrative syntheses, systematic syntheses (although references were examined), editorials, commentaries, conference abstracts lacking full-text publication, case reports (n<10), and preclinical investigations (in vitro, ex vivo, animal models).

Publication Characteristics: Scholarly manuscripts disseminated in the Anglophone vernacular from January 1, 2017, to December 4, 2025, were integrated. The commencement date of 2017 was chosen as it antedated significant inclisiran trial disseminations.

Information Sources and Search Strategy

A rigorous and structured assessment of the literature in question was carried out across three separate databases: Scopus, ScienceDirect, and PubMed. The inquiry was finalized on December 4, 2025. The search methodology was formulated to optimize sensitivity while preserving specificity for inclisiran and inflammatory biomarkers:

Search Query: (inclisiran) AND (“C-reactive protein” OR CRP OR “interleukin-6” OR “IL-6” OR “tumor necrosis factor” OR TNF)

Filters Applied: - Publication years: 2017-2025 - Language: English - Document type: Article (original research) - Source type: Journal

The inquiry methodology was replicable throughout all repositories with negligible syntactic alterations as necessitated by distinct database frameworks. No supplementary manual exploration or obscure literature examination was undertaken.

Selection Process

Two independent reviewers executed the evaluation of titles and abstracts, and subsequently conducted a meticulous analysis of the comprehensive texts in accordance with predetermined eligibility parameters. Discrepancies were adjudicated through discourse or consultation with a tertiary reviewer when concord could not be attained. The evaluation procedure was implemented in two phases:

Stage 1 - Title and Abstract Screening: All acquired documents were subjected to a methodical appraisal of titles and summaries, utilizing expansive inclusion parameters (in cases of ambiguity, the documents were incorporated for exhaustive full-text analysis). Documents were discarded if they were manifestly extraneous (for instance, not related to inclisiran, comprising animal investigations, or categorized as review manuscripts).

Stage 2 - Full-Text Screening: Full-text manuscripts were evaluated in accordance with all eligibility standards. Justifications for exclusion were recorded systematically. The assessment of inter-rater reliability involved the application of Cohen's kappa coefficient, with $\kappa \geq 0.70$ recognized as a marker of significant agreement.

Data Collection Process

Data retrieval was executed independently by two assessors utilizing a uniform, pre-validated retrieval tool. Inconsistencies were addressed through discourse. For each investigation integrated into the evaluation, we scrupulously retrieved:

Study Characteristics: Initial contributor, year of dissemination, scholarly periodical, country, methodological framework, sample size, length of monitoring, financial support source.

Population Characteristics: Demographic parameters such as chronological age and gender distribution, baseline levels of low-density lipoprotein cholesterol (LDL-C), the existence of cardiovascular ailments, and the condition of familial hypercholesterolemia.

Intervention Details: Inclisiran dosage, administration timetable, mode of delivery, and concomitant lipid-lowering therapeutic regimen.

Comparator Details: Type of comparator (placebo, active treatment), background therapy.

Outcome Data: Inflammatory biomarker levels at baseline and follow-up, absolute and percentage changes, statistical significance (p-values, confidence intervals), LDL-C changes for correlation analysis.

Safety Data: Adverse occurrences, reactions at the site of administration, and significant adverse incidents.When data were reported in graphical format only, values were extracted using digital plot digitizer software. When multiple timepoints were reported, we extracted data from the longest follow-up duration. Study authors were not contacted for additional unpublished data.

Risk of Bias Evaluation

The potential for bias was evaluated independently by a duo of reviewers employing the Cochrane Risk of Bias tool version 2.0 (RoB 2.0) specifically designed for randomized controlled trials.[24] The instrument assesses five distinct domains: (1) the process of randomization, (2) deviations from the prescribed interventions, (3) absence of outcome data, (4) evaluation of the outcome, and (5) selection of the reported findings. Each domain was rated as "low risk," "some concerns," or "high risk," with an overall risk of bias judgment derived algorithmically. Disagreements were resolved through discussion.For observational research, the Newcastle-Ottawa Scale (NOS) was devised for the purpose of quality evaluation, assessing the domains of selection, comparability, and outcomes, where scores of ≥ 7 are regarded as indicative of high quality. ***However, no observational studies met final inclusion criteria.***

Data Synthesis

With regard to the inconsistencies in participant demographics, intervention approaches, and outcome reporting, we resolved to implement a narrative synthesis instead of pursuing a quantitative meta-analysis. The synthesis was structured according to:

1. **Study Characteristics:** An exposition of the studies incorporated, the demographics examined, and the evaluation of methodological rigor.
2. **Inflammatory Biomarker Outcomes:** The integration of hs-CRP, IL-6, TNF-α, and various other inflammatory biomarker data across multiple research studies, encompassing the directionality of effects, the extent of changes observed, and the statistical significance of these findings.
3. **Relationship to LDL-C Lowering:** Qualitative evaluation of the relationship between the reduction of LDL-C and alterations in inflammatory biomarker levels.
4. **Safety and Tolerability:** Summary of negative outcomes associated with the administration of inclisiran.

Results are presented in summary tables and described narratively. The inspection of statistical disparity (I^2 figure) was not meaningful as a result of employing a narrative synthesis method. The certainty of evidence was evaluated using GRADE (Grading of Recommendations Assessment, Development and Evaluation) criteria, considering risk of bias, inconsistency, indirectness, imprecision, and publication bias.[25]

III. RESULT AND DISCUSSION

Study Selection

The literature search identified 304 records across three databases: Scopus (n=212), ScienceDirect (n=85), and PubMed (n=7). After removing 32 duplicates, 272 unique records underwent title and abstract screening. Of these, 262 were excluded (not about inclisiran: n=166; animal/in vitro studies: n=68; reviews/meta-analyses: n=25; other reasons: n=3), leaving 10 records for full-text review. A supplementary five records were uncovered via the process of citation analysis of studies that were included, thereby elevating the cumulative total to fifteen full-text articles subjected to an assessment of their eligibility. Backward citation searching (screening reference lists of included studies) was performed to identify any further eligible publications. Eleven scholarly articles were excluded subsequent to a comprehensive evaluation of their full texts (absence of inflammatory biomarker data: n=9; limited to conference abstract: n=1; duplicate publication: n=1). Ultimately, a total of 4 studies were incorporated into the qualitative synthesis. The 4 studies included comprised 4 randomized controlled trials. The methodology utilized for study selection is illustrated in the **PRISMA flow diagram (Figure 1)**. Inter-rater reliability for title and abstract screening demonstrated an exceptional level (κ=0.89), while full-text screening exhibited a substantial degree of agreement (κ=0.85), thereby suggesting a high level of consistency among the reviewers.



Fig 1. PRISMA flow diagram of this systematic review

Study Characteristics

The 4 included studies comprised 4 randomized controlled trials, published between 2017 and 2025. The four prominent randomized controlled trials (ORION-1, ORION-9, ORION-10, ORION-11) recruited a cumulative total of 4,161 subjects from a variety of geographical locales, encompassing North America, Europe, South Africa, and the Asia-Pacific region.

ORION-1 was a phase 2, double-blind, placebo-controlled, dose-ranging trial enrolling 501 patients with elevated LDL-C and high cardiovascular risk.[10] Patients were randomized to inclisiran (100-500 mg) or placebo with various dosing regimens (single dose, two doses 90 days apart, or dosing every 90 or 180 days) for 240 days.

ORION-9 was a phase 3, double-blind, placebo-controlled trial specifically enrolling 482 patients with heterozygous familial hypercholesterolemia on maximally tolerated statin therapy.[11] Patients received inclisiran 284 mg or placebo at days 1, 90, then every 180 days for 540 days.

ORION-10 and **ORION-11** were identically designed phase 3, double-blind, placebo-controlled trials enrolling patients with ASCVD or ASCVD-risk equivalents on maximally tolerated statin therapy.[13] ORION-10 enrolled 1,561 patients in North America, while ORION-11 enrolled 1,617 patients in Europe and South Africa. Both clinical trials administered inclisiran at a dosage of 284 mg on days 1 and 90, followed by subsequent doses every 180 days over a total duration of 540 days.Baseline characteristics were generally similar across trials. The mean age of participants varied between 54 and 64 years, exhibiting a male predominance that ranged from 50% to 75%. The average baseline concentrations of LDL-C varied between 104 and 153 mg/dL, reflecting the inclusion of both primary and secondary prevention cohorts. All studies required the implementation of background statin therapy, administered at maximally tolerated dosages, with or without the addition of ezetimibe. Study characteristics are summarized in Table 1.

Table 1. Study Characteristicsof selected studies

Studi ID	Year	Study Design	Country	Follow-up	Schedule	Background	Adverse Events
ORION-1	2017	Phase 2 RCT	Multi-national	240 days	Days1,90; Q90D/Q180D	Statin ± ezetimibe	ISR 5.1%
ORION-9	2020	Phase 3 RCT	Multi-national	540 days	Days 1,90, Q180D	Max statin	ISR 4.7%
ORION-10	2020	Phase 3 RCT	North America	540 days	Days 1,90, Q180D	Max statin	ISR 2.6%
ORION-11	2020	Phase 3 RCT	Europe, S.Africa	540 days	Days 1,90, Q180D	Max statin	ISR 2.8%

Risk of Bias Assessment

All four included RCTs demonstrated low risk of bias across all domains of the Cochrane RoB 2.0 tool (Figure 2). Randomization procedures were appropriate with adequate allocation concealment. The double-blinding of participants, personnel, and outcome evaluators was rigorously upheld. The absence of outcome data was negligible (<5% across all trials) and equitably distributed among the groups. Inflammatory biomarker measurements were conducted using validated, standardized assays in central laboratories, minimizing measurement bias. Pre-defined analytical frameworks were disseminated, and all predetermined outcomes were documented, signifying a minimal likelihood of selective reporting bias. The comprehensive quality of the evidence was appraised as HIGH according to GRADE criteria for the principal outcome (hs-CRP), signifying the incorporation of substantial, rigorously executed randomized controlled trials (RCTs) exhibiting uniform results and a minimal risk of bias. However, the evidence was downgraded to MODERATE for certainty regarding anti-inflammatory effects due to imprecision (wide confidence intervals crossing the null) and indirectness (hs-CRP as a surrogate marker rather than clinical outcomes).



Fig 2. Risk of Bias of selected studies based on Cochrane Risk of Bias tool version 2.0

Effects on High-Sensitivity C-Reactive Protein

All four major RCTs reported hs-CRP data as a pre-specified safety or exploratory outcome. Across diverse investigations, inclisiran administration exhibited neutral influences on hs-CRP concentrations, revealing no statistically significant variances in comparison to the placebo group.

In **ORION-1**, baseline median hs-CRP was approximately 2.1 mg/L in both inclisiran and placebo groups.[10] At day 240, there were no significant changes in hs-CRP levels across any inclisiran dose regimen compared to placebo (p values not significant). The trial report stated that "no clinically meaningful changes in inflammatory markers were observed."

In **ORION-9**, the median baseline level of hs-CRP was recorded at 1.8 mg/L within the inclisiran cohort, whereas it was measured at 1.7 mg/L in the placebo cohort.[12] At the 510-day mark, hs-CRP exhibited an increment of 3.5% in the inclisiran group when juxtaposed with the placebo group, a variation that lacked statistical significance (p=0.42). The slight elevation in hs-CRP did not demonstrate a correlation with the substantial 47.9% decrease in LDL-C that was attained through the administration of inclisiran.

In **ORION-10**, median baseline hs-CRP was 2.3 mg/L in the inclisiran group and 2.2 mg/L in the placebo group.[13] At day 510, hs-CRP increased by 8.5% in the inclisiran group compared to placebo (p=0.18). Despite robust LDL-C reduction of 52.3%, no anti-inflammatory effect was observed.

In **ORION-11**, median baseline hs-CRP was 2.1 mg/L in both groups.[13] At day 510, hs-CRP increased by 6.2% in the cohort receiving inclisiran, as opposed to the placebo group, the statistical significance was recorded at p=0.28. Similar to ORION-10, the 49.9% LDL-C reduction was not accompanied by hs-CRP lowering.

Importantly, hs-CRP levels remained within clinically normal ranges (<3 mg/L) throughout all trials, and no patients experienced clinically significant elevations suggestive of acute inflammatory processes. The consistent neutral effect on hs-CRP across diverse patient populations (familial hypercholesterolemia, ASCVD, varying baseline LDL-C levels) and geographical regions strengthens confidence in this finding.

Effects on Other Inflammatory Biomarkers

The research encompassed within the evaluation failed to produce any concrete evidence concerning the concentrations of interleukin-6 (IL-6) or tumor necrosis factor-alpha (TNF-α). Likewise, additional inflammatory biomarkers such as IL-1β, IL-8, IL-10, adhesion molecules (including VCAM-1, ICAM-1, and

E-selectin), chemokines (notably MCP-1), or acute phase reactants (like fibrinogen and serum amyloid A) were absent from the reports of any of the principal randomized controlled trials (RCTs). Interleukin-6 (IL-6) is unequivocally a principal catalyst for the synthesis of C-reactive protein (CRP) in the liver and is instrumental in the inflammatory processes associated with atherosclerotic cardiovascular disease (ASCVD). It independently predicts cardiovascular events, highlighting its importance in risk stratification and preventive cardiology.[26] Tumor necrosis factor-alpha (TNF-α) is a critical pro-inflammatory cytokine that significantly contributes to endothelial dysfunction and plaque destabilization, mechanisms central to atherosclerosis and cardiovascular diseases.[27] The absence of data on these biomarkers limits comprehensive assessment of inclisiran's inflammatory signature.

The Association of LDL-C Lowering and Variations in Inflammatory Biomarkers

Throughout all conducted trials, substantial and persistent reductions in LDL-C levels (varying between 47.9% and 52.6%) did not correlate with analogous decreases in hs-CRP. Indeed, numerical elevations in hs-CRP (although not reaching statistical significance) were noted in ORION-9, -10, and -11, notwithstanding the considerable reduction in LDL-C. This observed dissociation indicates that the cardiovascular advantages of inclisiran are predominantly facilitated through the reduction of LDL-C rather than through direct anti-inflammatory mechanisms.The correlation observed between the reduction of low-density lipoprotein cholesterol (LDL-C) and the concomitant decreases in high-sensitivity C-reactive protein (hs-CRP) within statin clinical trials elucidates a multifaceted interaction between lipid profiles and inflammatory responses in the context of cardiovascular risk mitigation. While some studies indicate that statins effectively lower hs-CRP levels, the degree of reduction varies with the type of statin and whether it is combined with other therapies, such as ezetimibe, where post-hoc analyses suggested possible anti-inflammatory effects.[28,29] However, these findings remain controversial, and whether PCSK9 inhibition has anti-inflammatory properties independent of LDL-C lowering remains unresolved.

Safety and Acceptability

Inclisiran exhibited a commendable profile of safety and tolerability across all conducted trials. The predominant adverse event reported was mild reactions at the injection site, which were observed in 2.6-5.1% of patients administered inclisiran, in contrast to 0.5-1.0% among those receiving placebo. These reactions were generally characterized as mild, self-resolving, and did not necessitate the cessation of treatment.Importantly, there was no evidence indicating the prevalence of extensive inflammatory responses, cytokine storm syndrome, or detrimental immune-mediated effects. Checks on liver performance stayed stable, indicating no symptoms of hepatotoxicity. Adverse events of a severe nature were distributed uniformly between the inclisiran and placebo cohorts during all trials. The biannual management plan was favorably received by both patients and healthcare professionals. The lack of any significant impact on high-sensitivity C-reactive protein (hs-CRP), along with the non-occurrence of any inflammatory adverse events, offers a measure of confidence concerning the safety profile associated with sustained PCSK9 inhibition via RNA interference (RNAi) technology. The long-term safety profile will be further characterized in ongoing cardiovascular outcomes trials (ORION-4, VICTORION-2 PREVENT).

Discussion

Principal Discoveries

This systematic review performed an extensive examination of the influence of inclisiran on inflammatory biomarkers in adult populations diagnosed with hypercholesterolemia or atherosclerotic cardiovascular disease (ASCVD). Our primary discoveries are: (1) inclisiran intervention achieves substantial and sustained LDL-C reductions (approximately 50%) without significantly modifying hs-CRP levels; (2) across four high-caliber RCTs enrolling over 4,000 participants, hs-CRP remained neutral or exhibited modest, non-significant elevations with inclisiran; (3) no data on other crucial inflammatory biomarkers (IL-6, TNF-α) were documented in principal trials; and (4) the disassociation between LDL-C diminution and inflammatory biomarker alterations implies inclisiran's cardiovascular advantages are chiefly mediated through lipid reduction rather than direct anti-inflammatory mechanisms.

Interpretation and Mechanistic Considerations

The neutral inflammatory profile of inclisiran possesses numerous plausible mechanistic elucidations. First, a synthetic small interfering RNA (siRNA) proficiently diminishes low-density lipoprotein cholesterol (LDL-C) by obstructing the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) in hepatocytes, which is vital for modulating LDL receptor degradation.[30] While preclinical investigations have delineated PCSK9 expression in immune cells and vascular tissues, indicating prospective immunomodulatory functions, these ramifications may not transmute into clinically significant systemic inflammatory alterations in humans.[15,16,30]

Second, the correlation between low-density lipoprotein cholesterol (LDL-C) reduction and inflammation is multifaceted and presumably mutual. the diminishment of LDL-C in isolation may not adequately modify systemic inflammatory indices such as high-sensitivity C-reactive protein (hsCRP), which signifies the hepatic acute phase response and the overall inflammatory load.[31] The temporal dynamics of inflammatory biomarker variations may diverge from lipid alterations, with prospective advantages necessitating prolonged observation or emerging solely in particular patient cohorts.

Third, the precise mechanism through which PCSK9 inhibition operates may have an impact on inflammatory responses. Monoclonal antibodies (evolocumab, alirocumab) bind extracellular PCSK9 protein, while inclisiran reduces intracellular PCSK9 mRNA and protein synthesis through RNAi. Whether these mechanistic differences translate to differential inflammatory effects remains speculative. Post-hoc analyses from FOURIER (evolocumab) suggested possible hs-CRP reductions, though these findings were inconsistent and of uncertain clinical significance.[29]

Fourth, the high-sensitivity C-reactive protein (hs-CRP) is acknowledged as a significant marker for cardiovascular risk, largely mirroring the liver's acute-phase response spurred by interleukin-6 (IL-6). Nevertheless, it may not entirely encompass the intricate inflammatory mechanisms implicated in atherosclerosis, such as vascular inflammation, immune cell activation, and inflammasome functionality.[32] The scarcity of information regarding alternative inflammatory biomarkers (IL-6, TNF-α, IL-1β) in inclisiran investigations constitutes a considerable constraint in comprehensively delineating its inflammatory profile. The impartial hs-CRP indication with inclisiran diverges from variable accounts of hs-CRP diminution with PCSK9 monoclonal antibodies (mAbs).[29]. This divergence may derive from essential mechanistic distinctions: mAbs neutralize circulating PCSK9 protein, potentially disrupting extracellular PCSK9-mediated signaling in immune cells. [15], whereas inclisiran inhibits intracellular hepatic PCSK9 production through RNA interference.[9] Whether extracellular versus intracellular PCSK9 reservoirs possess divergent functions in inflammation remains an unresolved inquiry.

Comparison with Other Lipid-Lowering Therapies

Statins, extensively acknowledged for their ability to regulate lipid concentrations, also demonstrate considerable pleiotropic effects, particularly anti-inflammatory characteristics that enhance cardiovascular health. Investigations reveal that statins can diminish high-sensitivity C-reactive protein (hs-CRP) concentrations by approximately 15-30%, with atorvastatin exhibiting the most pronounced influences on inflammatory biomarkers such as IL-6 and TNF-α.[33,34] The JUPITER trial specifically elucidated that rosuvastatin diminished cardiovascular occurrences in individuals with heightened hs-CRP but normative LDL-C, endorsing inflammation as a distinct therapeutic objective.[35] It is essential to contextualize our discoveries within the circumstance that nearly all trial subjects were receiving concomitant statin treatment. This 'floor effect' may have constrained the capacity to identify any supplementary hs-CRP reduction from inclisiran.Monoclonal antibodies directed against PCSK9 have demonstrated heterogeneous effects on the levels of inflammatory biomarkers. In the FOURIER trial, evolocumab accomplished a 59% reduction in LDL-C alongside a modest decrease in hs-CRP (approximately 20%), although this was not an a priori specified outcome and results were inconsistent across various analyses.[29]

In the ODYSSEY OUTCOMES investigation, alirocumab exhibited considerable decreases in low-density lipoprotein cholesterol (LDL-C) concentrations, attaining a median decline from 2.3 to 1.0 mmol/L; however, it revealed no noteworthy impact on high-sensitivity C-reactive protein (hs-CRP) concentrations notwithstanding this significant LDL-C reduction. Click or tap here to enter text.These findings, when

amalgamated with our exhaustive examination of inclisiran information, suggest that the suppression of PCSK9 in seclusion may be deficient in substantial anti-inflammatory impacts in human participants.Ezetimibe, designated as an intestinal cholesterol uptake inhibitor, has been demonstrated to diminish low-density lipoprotein cholesterol (LDL-C) by approximately 15-25% when administered either in isolation or in conjunction with statins, whilst exerting a negligible impact on high-sensitivity C-reactive protein (hs-CRP) concentrations. [38] Bempedoic acid, an ATP citrate lyase antagonist, has exhibited considerable effectiveness in diminishing both low-density lipoprotein cholesterol (LDL-C) and high-sensitivity C-reactive protein (hs-CRP), which are paramount determinants in cardiovascular risk administration.[39]

Clinical Implications

Our discoveries possess numerous significant clinical ramifications. First, inclisiran's neutral inflammatory profile indicates that its cardiovascular advantages will be predominantly facilitated through LDL-C diminishment, aligning with the "lower is better" paradigm for LDL-C reduction. Healthcare practitioners may confidently utilize inclisiran for the objective of attaining substantial decrements in LDL-C concentrations, without presuming any ancillary benefits related to anti-inflammatory effects.

Second, People with chronic cardiovascular threats, notwithstanding effective LDL-C control, may have to rely on combined tactics that encompass both lipid and inflammatory considerations. The CANTOS trial evidenced that IL-1β suppression via canakinumab diminished cardiovascular occurrences independently of LDL-C reduction, thereby substantiating this methodology. Ongoing investigations are assessing combinatory therapies, encompassing inclisiran in conjunction with anti-inflammatory agents.

Third, the biannual administration protocol of inclisiran presents pragmatic benefits for sustained compliance, particularly in individuals necessitating vigorous LDL-C reduction who encounter difficulties with quotidian oral pharmacotherapy or recurrent injections. The neutral inflammatory profile affords confidence concerning prolonged safety.

Fourth, the selection of patients for inclisiran administration should underscore individuals demonstrating elevated low-density lipoprotein cholesterol (LDL-C) concentrations who require further diminution beyond the thresholds delineated by maximally tolerated statin therapy, rather than concentrating exclusively on those manifesting elevated inflammatory markers. This cohort includes individuals diagnosed with familial hypercholesterolemia, those with atherosclerotic cardiovascular disease (ASCVD) exhibiting insufficient control of LDL-C levels, in addition to patients who manifest intolerance to statin therapy.

Strengths and Limitations

This comprehensive review possesses numerous advantages. We conformed to the rigorous PRISMA 2020 framework, encompassing thorough database inquiries, independent screening for redundancies, data extraction, and a validated evaluation of bias risk. The randomized controlled trials (RCTs) included in the examination were substantial in magnitude, methodologically robust, double-blinded, and exhibited a minimal risk of bias, thereby furnishing high-quality empirical evidence. The consistency of findings across diverse patient demographics and geographic regions enhances the dependability of the observed neutral inflammatory effect. Nonetheless, it is crucial to acknowledge considerable limitations that necessitate contemplation. First, the evidence corpus is confined to hs-CRP, with no documented information on IL-6, TNF-α, or other inflammatory biomarkers that may yield supplementary insights. Second, hs-CRP was predominantly a safety or exploratory outcome rather than a predetermined primary endpoint, potentially constraining statistical robustness and premeditated analyses. Third, follow-up duration was restricted to 240-540 days; long-term ramifications on inflammatory markers remain uncertain. Fourth, subgroup analyses exploring inflammatory responses within distinct patient demographics (e.g., individuals manifesting elevated baseline hs-CRP levels, diabetes mellitus, metabolic syndrome) were not recorded.

Fifth, we cannot dismiss the possibility of publication bias, as unfavorable findings on inflammatory biomarkers may be underrepresented in the literature. Sixth, our inquiry was confined to three databases and English-language publications, potentially overlooking pertinent studies. Nevertheless, the incorporated trials signify the principal phase 2-3 RCTs that constitute the evidence base for inclisiran's regulatory endorsement, rendering it improbable that substantial additional data are available. Seventh, we did not

engage study authors for unpublished inflammatory biomarker data, which may reside in trial databases but was excluded from primary publications. The deficiency of individual patient-level data ultimately curtailed the feasibility of executing a meta-analysis and scrutinizing potential modifications of effect.Additionally, a fundamental constraint is that inflammatory biomarkers were secondary or exploratory endpoints in all incorporated RCTs. Consequently, the experimental trials were not adequately powered to discern clinically significant disparities in these parameters. The observed neutral effect on hs-CRP may denote a genuine null result, or it may suggest a type II error in which a subtle anti-inflammatory effect remained undetected due to the limitations of the sample size and the variability inherent in hs-CRP measurements. Post-hoc power computations are discouraged; thus, this intrinsic imprecision must be acknowledged.[25]

Future Research Directions

Several important research questions remain unanswered and warrant future investigation. First, Future trials should prioritize the inclusion of IL-6 measurement. As the key upstream regulator of CRP synthesis, a neutral effect on IL-6 would provide far stronger evidence for a lack of systemic anti-inflammatory activity than hs-CRP alone.[26]. Furthermore, given the success of targeting the IL-6 signaling pathway (e.g., via IL-1β inhibition in CANTOS [7]), this data is crucial for understanding inclisiran's position in the therapeutic arsenal against residual inflammatory risk.

Second, the correlation among PCSK9 concentrations, the diminution of LDL-C, and the alterations in inflammatory biomarker levels necessitates a systematic assessment. Whether the degree of PCSK9 suppression correlates with any inflammatory effects remains unknown. Pharmacodynamic studies that include sequential biomarker evaluations may clarify temporal relationships.

Third, subgroup evaluations scrutinizing inflammatory reactions in particular patient demographics are requisite. Individuals demonstrating metabolic syndrome, diabetes mellitus, chronic renal insufficiency, or elevated baseline inflammatory biomarkers may manifest disparate therapeutic responses. Paradigms delineated in precision medicine are proficient in segregating cohorts that are projected to derive the utmost advantages from inclisiran.

Fourth, vascular imaging investigations employing positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) or alternative tracers could evaluate arterial wall inflammation directly, augmenting systemic biomarker assessments. Such investigations would ascertain whether inclisiran has an impact on local vascular inflammation notwithstanding neutral systemic biomarker consequences.

Fifth, the continuous cardiovascular outcomes investigations ORION-4 (aimed enrollment 15,000 subjects with ASCVD) and VICTORION-2 PREVENT will furnish conclusive evidence pertaining to inclisiran’s influences on significant adverse cardiovascular occurrences. Secondary analyses from these investigations should scrutinize correlations between inflammatory biomarker alterations and clinical outcomes.

Sixth, comparative efficacy investigations assessing inclisiran in relation to PCSK9 monoclonal antibodies or alternative lipid-reducing interventions on inflammatory results would elucidate therapeutic choice. Direct comparative trials with extensive biomarker evaluations are requisite.

Ultimately, mechanistic inquiries examining the impact of inclisiran on immune cell performance, endothelial function, and atheromatous plaque biology may produce significant insights into potential pleiotropic effects extending beyond modifications in systemic biomarkers. Intricate methodologies such as single-cell RNA sequencing, flow cytometry, and ex vivo functional evaluations can illuminate the effects at the cellular level.

IV. CONCLUSION

This systematic review elucidates that inclisiran intervention exerts a neutral influence on the systemic inflammatory biomarker hs-CRP among varied patient cohorts, notwithstanding its substantial reductions in LDL-C levels. The complete absence of empirical evidence concerning pivotal cytokines such as IL-6 and TNF-α represents a significant shortcoming in our comprehension of its pleiotropic attributes. Current high-quality evidence suggests inclisiran's cardiovascular benefit is mediated predominantly, if not exclusively, through LDL-C lowering—the paramount driver of atherogenesis. this underscores its function

as a powerful, sustained lipid-reducing pharmacological agent devoid of substantial off-target anti-inflammatory consequences. For individuals exhibiting elevated residual inflammatory risk, integrative approaches aimed at mitigating inflammation may prove essential. Future cardiovascular outcome trials and mechanistic studies must incorporate comprehensive biomarker panels to definitively resolve inclisiran's inflammatory signature and guide personalized therapy.

REFERENCES

[1] Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. *Nature*. 2011;473(7347):317-325. doi:10.1038/nature10146

[2] Ridker PM. From C-Reactive Protein to Interleukin-6 to Interleukin-1. *Circ Res*. 2016;118(1):145-156. doi:10.1161/CIRCRESAHA.115.306656

[3] Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. ***Eur Heart J.*** 2017;38(32):2459-2472. doi:10.1093/eurheartj/ehx144

[4] Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*. 2019;139(25). doi:10.1161/CIR.0000000000000625

[5] Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. ***New England Journal of Medicine***. 2008;359(21):2195-2207. doi:10.1056/NEJMoa0807646

[6] Bohula EA, Giugliano RP, Leiter LA, et al. Inflammatory and Cholesterol Risk in the FOURIER Trial. *Circulation*. 2018;138(2):131-140. doi:10.1161/CIRCULATIONAHA.118.034032

[7] Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. ***New England Journal of Medicine***. 2017;377(12):1119-1131. doi:10.1056/NEJMoa1707914

[8] Seidah NG, Benjannet S, Wickham L, et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): Liver regeneration and neuronal differentiation. *Proceedings of the National Academy of Sciences*. 2003;100(3):928-933. doi:10.1073/pnas.0335507100

[9] Fitzgerald K, White S, Borodovsky A, et al. A Highly Durable RNAi Therapeutic Inhibitor of PCSK9. *New* ***England Journal of Medicine***. 2017;376(1):41-51. doi:10.1056/NEJMoa1609243

[10] Ray KK, Landmesser U, Leiter LA, et al. Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol. ***New England Journal of Medicine***. 2017;376(15):1430-1440. doi:10.1056/NEJMoa1615758

[11] Lamb YN. Inclisiran: First Approval. *Drugs*. 2021;81(3):389-395. doi:10.1007/s40265-021-01473-6

[12] Raal FJ, Kallend D, Ray KK, et al. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. *New England Journal of Medicine*. 2020;382(16):1520-1530. doi:10.1056/NEJMoa1913805

[13] Ray KK, Wright RS, Kallend D, et al. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol**.** ***New England Journal of Medicine***. 2020;382(16):1507-1519. doi:10.1056/NEJMoa1912387

[14] CHMP. *Leqvio, INN-Inclisiran*. www.ema.europa.eu/contact

[15] Ferri N, Tibolla G, Pirillo A, et al. Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels. *Atherosclerosis*. 2012;220(2):381-386. doi:10.1016/j.atherosclerosis.2011.11.026

[16] Ding Z, Wang X, Liu S, et al. PCSK9 expression in the ischaemic heart and its relationship to infarct size, cardiac function, and development of autophagy. *Cardiovasc Res*. 2018;114(13):1738-1751. doi:10.1093/cvr/cvy128

[17] Cheng JM, Oemrawsingh RM, Garcia-Garcia HM, et al. PCSK9 in relation to coronary plaque inflammation: Results of the ATHEROREMO-IVUS study. *Atherosclerosis*. 2016;248:117-122. doi:10.1016/j.atherosclerosis.2016.03.010

[18] Almontashiri NAM, Vilmundarson RO, Ghasemzadeh N, et al. Plasma PCSK9 Levels Are Elevated with Acute Myocardial Infarction in Two Independent Retrospective Angiographic Studies. *PLoS One*. 2014;9(9):e106294. doi:10.1371/journal.pone.0106294

[19] Tucker B, Ong KL, Robledo K, Keech A, Patel S. The association of inflammation, triglycerides and lipoprotein(a) with cardiovascular events in the UK Biobank. ***Eur Heart J.*** 2024;45(Supplement_1). doi:10.1093/eurheartj/ehae666.2751

[20] Lamabadusuriya D, Jayawardene P, Cader FA, Wickramarachchi U. High-sensitivity C-reactive protein and its role in coronary atherosclerotic disease: a review of current literature. ***Postgrad Med J.*** Published online June 30, 2025. doi:10.1093/postmj/qgaf093

[21] Kaptoge S, Seshasai SRK, Gao P, et al. Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis. ***Eur Heart J.*** 2014;35(9):578-589. doi:10.1093/eurheartj/eht367

[22] Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E. Elevation of Tumor Necrosis Factor-α and Increased Risk of Recurrent Coronary Events After Myocardial Infarction. *Circulation*. 2000;101(18):2149-2153. doi:10.1161/01.CIR.101.18.2149

[23] Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. ***BMJ.*** Published online March 29, 2021:n71. doi:10.1136/bmj.n71

[24] Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. ***BMJ.*** Published online August 28, 2019:l4898. doi:10.1136/bmj.l4898

[25] Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. ***BMJ***. 2008;336(7650):924-926. doi:10.1136/bmj.39489.470347.AD

[26] Santos RD, Rocha VZ. Bringing interleukin-6 complexity to preventive cardiology practice? ***Eur J Prev Cardiol.*** 2020;27(2):119-121. doi:10.1177/2047487319876765

[27] Huang Y, Yan L, Rong S, Haller H, Kirch T. TNF-α induces endothelial dysfunction via PKC-ζ-dependent NADPH oxidase activation. ***Journal of Huazhong University of Science and Technology [Medical Sciences].*** 2012;32(5):642-647. doi:10.1007/s11596-012-1011-9

[28] Xue Z, Ye M, Jiang H, et al. The Effect of Different Statin-Based Lipid-Lowering Strategies on C-Reactive Protein Levels in Patients With Stable Coronary Artery Disease. *Clin Cardiol*. 2024;47(6). doi:10.1002/clc.24301

[29] Bohula EA, Giugliano RP, Leiter LA, et al. Inflammatory and Cholesterol Risk in the FOURIER Trial. *Circulation*. 2018;138(2):131-140. doi:10.1161/CIRCULATIONAHA.118.034032

[30] Marrs JC, Anderson SL. Inclisiran for the treatment of hypercholesterolaemia. *Drugs Context*. 2024;13:1-9. doi:10.7573/dic.2023-12-3

[31] Katamine M, Minami Y, Ako J. High-Sensitivity C-Reactive Protein and Residual Inflammatory Risk in Coronary Artery Disease: The Pathophysiology, Prognosis, and Emerging Therapies. ***J Atheroscler Thromb.*** Published online 2025:RV22044. doi:10.5551/jat.RV22044

[32] Menon T, Chahil V, Patel D, Grancorvitz C, Vijayraghavan K. Inflammation and cardiovascular disease – Part I: Mechanisms and biomarkers. *Global Translational Medicine*. 2025;4(3):1. doi:10.36922/GTM025100023

[33] Sabeel S, Motaung B, Nguyen KA, et al. Impact of statins as immune-modulatory agents on inflammatory markers in adults with chronic diseases: A systematic review and meta-analysis. *PLoS One*. 2025;20(5):e0323749. doi:10.1371/journal.pone.0323749

[34] Khan S, Huda B, Bhurka F, Patnaik R, Banerjee Y. Molecular and Immunomodulatory Mechanisms of Statins in Inflammation and Cancer Therapeutics with Emphasis on the NF-κB, NLRP3 Inflammasome, and Cytokine Regulatory Axes. ***Int J Mol Sci.*** 2025;26(17):8429. doi:10.3390/ijms26178429

[35] Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. ***New England Journal of Medicine***. 2008;359(21):2195-2207. doi:10.1056/NEJMoa0807646

[36] Goodman SG, Steg PG, Poulouin Y, et al. Long-Term Efficacy, Safety, and Tolerability of Alirocumab in 8242 Patients Eligible for 3 to 5 Years of Placebo-Controlled Observation in the ODYSSEY OUTCOMES Trial. ***J Am Heart Assoc***. 2023;12(18). doi:10.1161/JAHA.122.029216

[37] Landmesser U, McGinniss J, Steg PG, et al. Achievement of ESC/EAS LDL-C treatment goals after an acute coronary syndrome with statin and alirocumab. ***Eur J Prev Cardiol***. 2022;29(14):1842-1851. doi:10.1093/eurjpc/zwac107

[38] Bays HE. Cholesterol-lowering drugs: Focus on Ezetimibe: Cholesterol-lowering drugs: Focus on ezetimibe. ***European Atherosclerosis Journal***. 2022;1(1):14-24. doi:10.56095/eaj.v1i1.8

[39] Nicholls SJ, Nelson AJ, Lincoff AM, et al. Impact of Bempedoic Acid on Total Cardiovascular Events. ***JAMA Cardiol***. 2024;9(3):245. doi:10.1001/jamacardio.2023.5155